NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $5.50 +0.07 (+1.29%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.50 0.00 (0.00%) As of 04/17/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vir Biotechnology Stock (NASDAQ:VIR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vir Biotechnology alerts:Sign Up Key Stats Today's Range$5.34▼$5.5350-Day Range$5.19▼$9.8552-Week Range$4.95▼$14.45Volume713,272 shsAverage Volume1.34 million shsMarket Capitalization$754.29 millionP/E RatioN/ADividend YieldN/APrice Target$33.57Consensus RatingModerate Buy Company OverviewVir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More… Vir Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreVIR MarketRank™: Vir Biotechnology scored higher than 52% of companies evaluated by MarketBeat, and ranked 455th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 4 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vir Biotechnology are expected to grow in the coming year, from ($3.92) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.56% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 28.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.56% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 28.30%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.89 News SentimentVir Biotechnology has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $663,525.00 in company stock.Percentage Held by Insiders15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Stock News HeadlinesVir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comStock Movers: Moderna, Tesla, Canada GooseMarch 31, 2025 | bloomberg.comTrump and Musk fight backIs there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.April 20, 2025 | Brownstone Research (Ad)Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the companyMarch 28, 2025 | finance.yahoo.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial ResultsMarch 21, 2025 | prnewswire.comVir enrols first subject in Phase III programme to assess CHD therapyMarch 14, 2025 | finance.yahoo.comVir Biotechnology enrolls first patient in ECLIPSE programMarch 13, 2025 | markets.businessinsider.comHepatitis D Market to Expand Significantly by 2034, States DelveInsight Report | Gilead Sciences, Eiger BioPharma, Janssen R&DMarch 4, 2025 | theglobeandmail.comSee More Headlines VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $7.34 at the start of the year. Since then, VIR shares have decreased by 25.1% and is now trading at $5.50. View the best growth stocks for 2025 here. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.09. The firm had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative trailing twelve-month return on equity of 36.71%. Read the conference call transcript. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's top institutional investors include Rhumbline Advisers (0.17%), GAMMA Investing LLC (0.03%), Wealth Enhancement Advisory Services LLC (0.01%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Howard Horn, Ann M Hanly, Steven J Rice, Sung Lee, Verneuil Vanina De, Brent Sabatini, Saira Ramasastry, Janet Napolitano and Charles Elliott Sigal. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vir Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V). Company Calendar Last Earnings2/26/2025Today4/19/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VIR CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees580Year FoundedN/APrice Target and Rating Average Stock Price Target$33.57 High Stock Price Target$110.00 Low Stock Price Target$14.00 Potential Upside/Downside+510.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-678.40% Pretax Margin-685.83% Return on Equity-36.71% Return on Assets-31.00% Debt Debt-to-Equity RatioN/A Current Ratio8.94 Quick Ratio8.94 Sales & Book Value Annual Sales$63.71 million Price / Sales11.84 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.47Miscellaneous Outstanding Shares137,143,000Free Float116,236,000Market Cap$754.29 million OptionableOptionable Beta1.14 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:VIR) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.